Quanterix’s fifth-generation digital immunoassay prostate specific antigen (PSA) test, demonstrated a 2-log improvement in sensitivity to measure PSA levels in patients following a radical prostatectomy.

The new PSA test based on proprietary single molecule array technology, forms a reliable predictor of five-year biochemical recurrence-free survival in men who have undergone radical prostatectomy for prostate cancer.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Quanterix Product Development senior director David Wilson said that the PSA assay could improve patient prognosis and inform clinical decisions for use of secondary therapy in individuals who have been treated surgically.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now